CBD has reduced affinity for CB receptors. It functions being an antagonist or partial antagonist at endogenous cannabinoid receptors (equally CB1 and CB2 receptor sorts in addition to other G-protein-coupled receptors [GPCRs]) by inhibiting full binding of direct ligands, and may act generally